Clinical Observation of Bifid Triple Viable Capsule in the Treatment of Ulcerative Colitis
10.6039/j.issn.1001-0408.2015.36.19
- VernacularTitle:双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床观察
- Author:
Lixin MAO
;
Yuanchun GUO
;
Jian QIAN
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Bifid triple viable capsule;
Intestinal mucous membrane barrier;
Efficacy;
Safety
- From:
China Pharmacy
2015;26(36):5095-5096
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the efficacy and safety of Bifid triple viable capsule in the treatment of ulcerative colitis (UC). METHODS:94 patients with UC were randomly divided into control group and research group. Control groups was given nutrition support,light diet and 5-amino salicylic acid and other conventional treatment;research group was additionally given 420 mg Bifid triple viable capsule,3 times aday. Treatment course for both group was 8 weeks. The clinical efficacy,and serum D-lac-tic acid,diamine oxidase(DAO)levels before and after treatment,and incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in research group was significantly higher than control group,the difference was statistically sig-nificant(P<0.05);after treatment,serum D-lactic acid,DAO levels in 2 groups were significantly lower than before,and re-search group was lower than control group,the differences were statistically significant(P<0.05 or P<0.01);and there was no sig-nificant difference in the incidence of adverse reactions(P>0.05). CONCLUSIONS:Based on the conventional treatment,both the efficacy and safety of Bifid triple viable capsule are good in the treatment of UC.
